Rapamycin extends murine lifespan but has limited effects on aging.

Aging is a major risk factor for a large number of disorders and functional impairments. Therapeutic targeting of the aging process may therefore represent an innovative strategy in the quest for novel and broadly effective treatments against age-related diseases. The recent report of lifespan extension in mice treated with the FDA-approved mTOR inhibitor rapamycin represented the first demonstration of pharmacological extension of maximal lifespan in mammals. Longevity effects of rapamycin may, however, be due to rapamycin's effects on specific life-limiting pathologies, such as cancers, and it remains unclear if this compound actually slows the rate of aging in mammals. Here, we present results from a comprehensive, large-scale assessment of a wide range of structural and functional aging phenotypes, which we performed to determine whether rapamycin slows the rate of aging in male C57BL/6J mice. While rapamycin did extend lifespan, it ameliorated few studied aging phenotypes. A subset of aging traits appeared to be rescued by rapamycin. Rapamycin, however, had similar effects on many of these traits in young animals, indicating that these effects were not due to a modulation of aging, but rather related to aging-independent drug effects. Therefore, our data largely dissociate rapamycin's longevity effects from effects on aging itself.

[1]  S. Austad,et al.  Chronic inhibition of mammalian target of rapamycin by rapamycin modulates cognitive and non-cognitive components of behavior throughout lifespan in mice , 2012, Neuroscience.

[2]  M. Antoch,et al.  Rapamycin extends lifespan and delays tumorigenesis in heterozygous p53+/− mice , 2012, Aging.

[3]  S. Schnell,et al.  Adult-Onset Fluoxetine Treatment Does Not Improve Behavioral Impairments and May Have Adverse Effects on the Ts65Dn Mouse Model of Down Syndrome , 2012, Neural plasticity.

[4]  A. Caccamo,et al.  Lifelong rapamycin administration ameliorates age‐dependent cognitive deficits by reducing IL‐1β and enhancing NMDA signaling , 2012, Aging cell.

[5]  M. Vinciguerra,et al.  Chronic mTOR inhibition by rapamycin induces muscle insulin resistance despite weight loss in rats , 2012, British journal of pharmacology.

[6]  A. Bartke,et al.  Rapamycin slows aging in mice , 2012, Cell cycle.

[7]  V. Anisimov,et al.  Rapamycin increases lifespan and inhibits spontaneous tumorigenesis in inbred female mice , 2011, Cell cycle.

[8]  Haishan Li,et al.  Rapamycin increases the yield and effector function of human γδ T cells stimulated in vitro , 2011, Cancer Immunology, Immunotherapy.

[9]  R. de Cabo,et al.  Rapamycin, but not resveratrol or simvastatin, extends life span of genetically heterogeneous mice. , 2011, The journals of gerontology. Series A, Biological sciences and medical sciences.

[10]  C. Parent,et al.  Constitutive reductions in mTOR alter cell size, immune cell development, and antibody production. , 2011, Blood.

[11]  M. Wacker,et al.  Muscle-specific inositide phosphatase (MIP/MTMR14) is reduced with age and its loss accelerates skeletal muscle aging process by altering calcium homeostasis , 2010, Aging.

[12]  Di Chen,et al.  With TOR, less is more: a key role for the conserved nutrient-sensing TOR pathway in aging. , 2010, Cell metabolism.

[13]  M. Antoch,et al.  Rapamycin extends maximal lifespan in cancer-prone mice. , 2010, The American journal of pathology.

[14]  Y. Deshaies,et al.  Chronic Rapamycin Treatment Causes Glucose Intolerance and Hyperlipidemia by Upregulating Hepatic Gluconeogenesis and Impairing Lipid Deposition in Adipose Tissue , 2010, Diabetes.

[15]  R. Broaddus,et al.  Loss of Inhibitory Insulin Receptor Substrate-1 Phosphorylation Is an Early Event in Mammalian Target of Rapamycin–Dependent Endometrial Hyperplasia and Carcinoma , 2010, Cancer Prevention Research.

[16]  J. Adamski,et al.  Quantification of steroids in human and mouse plasma using online solid phase extraction coupled to liquid chromatography tandem mass spectrometry , 2010 .

[17]  D. Sabatini,et al.  An Emerging Role of mTOR in Lipid Biosynthesis , 2009, Current Biology.

[18]  Yang Liu,et al.  mTOR Regulation and Therapeutic Rejuvenation of Aging Hematopoietic Stem Cells , 2009, Science Signaling.

[19]  Andreas Wenzel,et al.  Noninvasive, In Vivo Assessment of Mouse Retinal Structure Using Optical Coherence Tomography , 2009, PloS one.

[20]  Janet M. Thornton,et al.  Ribosomal Protein S6 Kinase 1 Signaling Regulates Mammalian Life Span , 2009, Science.

[21]  P. Rabinovitch,et al.  Cardiac aging in mice and humans: the role of mitochondrial oxidative stress. , 2009, Trends in cardiovascular medicine.

[22]  Marco Pahor,et al.  Rapamycin fed late in life extends lifespan in genetically heterogeneous mice , 2009, Nature.

[23]  Lars Eckardt,et al.  Echocardiographic assessment of global left ventricular function in mice , 2009, Laboratory animals.

[24]  P. Gosset,et al.  Low-dose aspirin prevents age-related endothelial dysfunction in a mouse model of physiological aging. , 2008, American journal of physiology. Heart and circulatory physiology.

[25]  C. Sigman,et al.  The Mammalian Target of Rapamycin Pathway as a Potential Target for Cancer Chemoprevention , 2007, Cancer Epidemiology Biomarkers & Prevention.

[26]  A. Di Cristofano,et al.  Pten loss in the mouse thyroid causes goiter and follicular adenomas: insights into thyroid function and Cowden disease pathogenesis. , 2007, Cancer research.

[27]  Alcino J. Silva,et al.  Investigation of age-related cognitive decline using mice as a model system: behavioral correlates. , 2006, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[28]  J. Larsen,et al.  Tacrolimus and Sirolimus Cause Insulin Resistance in Normal Sprague Dawley Rats , 2006, Transplantation.

[29]  Xiang-Mei Chen,et al.  Expression of tissue inhibitor of matrix metalloproteinase-1 in aging of transgenic mouse liver. , 2006, Chinese Medical Journal.

[30]  S. Olshansky,et al.  In pursuit of the longevity dividend , 2006 .

[31]  Matt Kaeberlein,et al.  Extension of chronological life span in yeast by decreased TOR pathway signaling. , 2006, Genes & development.

[32]  Matt Kaeberlein,et al.  Regulation of Yeast Replicative Life Span by TOR and Sch9 in Response to Nutrients , 2005, Science.

[33]  R. Douglas,et al.  Rapid quantification of adult and developing mouse spatial vision using a virtual optomotor system. , 2004, Investigative ophthalmology & visual science.

[34]  Di Chen,et al.  The TOR pathway interacts with the insulin signaling pathway to regulate C. elegans larval development, metabolism and life span , 2004, Development.

[35]  S. Benzer,et al.  Regulation of Lifespan in Drosophila by Modulation of Genes in the TOR Signaling Pathway , 2004, Current Biology.

[36]  Tibor Vellai,et al.  Genetics: Influence of TOR kinase on lifespan in C. elegans , 2003, Nature.

[37]  K Garber,et al.  Rapamycin's resurrection: a new way to target the cancer cell cycle. , 2001, Journal of the National Cancer Institute.

[38]  J. Ward,et al.  Pathology of Aging B6;129 Mice , 2001, Toxicologic pathology.

[39]  M. Hidalgo,et al.  The rapamycin-sensitive signal transduction pathway as a target for cancer therapy , 2000, Oncogene.

[40]  Gerd Kempermann,et al.  Experience-Induced Neurogenesis in the Senescent Dentate Gyrus , 1998, The Journal of Neuroscience.

[41]  Z. Kmieć,et al.  The effect of fasting and refeeding on thyroid follicule structure and thyroid hormone levels in young and old rats. , 1998, Archives of gerontology and geriatrics.

[42]  E. Fisher,et al.  Behavioral and functional analysis of mouse phenotype: SHIRPA, a proposed protocol for comprehensive phenotype assessment , 1997, Mammalian Genome.

[43]  S. Stepkowski,et al.  Distribution of sirolimus in rat tissue. , 1997, Clinical biochemistry.

[44]  A. Turturro,et al.  Longevity, Body Weight, and Neoplasia in Ad Libitum-Fed and Diet-Restricted C57BL6 Mice Fed NIH-31 Open Formula Diet , 1995, Toxicologic pathology.

[45]  D. Ingram,et al.  Relationship of body temperature stability to mortality in aging mice , 1985, Mechanisms of Ageing and Development.

[46]  B. Cinader,et al.  Aging and the immune system. , 1983, Clinical biochemistry.

[47]  C. Desjardins,et al.  Luteinizing hormone and testosterone secretion in young and old male mice. , 1982, The American journal of physiology.

[48]  Gerard P. Smith,et al.  Mesolimbicocortical dopamine terminal fields are necessary for normal locomotor and investigatory exploration in rats , 1980, Brain Research.

[49]  C. Frith,et al.  Hematologic and clinical chemistry findings in control BALB/c and C57BL/6 mice. , 1980, Laboratory animal science.

[50]  A. DeMaria,et al.  Recommendations Regarding Quantitation in M-Mode Echocardiography: Results of a Survey of Echocardiographic Measurements , 1978, Circulation.

[51]  I. Kunstýř,et al.  Gerontological data of C57BL/6J mice. II. Changes in blood cell counts in the course of natural aging. , 1976, Journal of Gerontology.

[52]  THE PURSUIT OF LONGEVITY , 1939, British medical journal.

[53]  O. Sakowitz,et al.  mTOR inhibition and erythropoiesis : microcytosis or anaemia ? , 2012 .

[54]  H. Fuchs,et al.  Mouse phenotyping. , 2011, Methods.

[55]  H. Fuchs,et al.  Systemic first-line phenotyping. , 2009, Methods in molecular biology.

[56]  Anne E Carpenter,et al.  CellProfiler: free, versatile software for automated biological image analysis. , 2007, BioTechniques.

[57]  D. Roberts,et al.  A rotarod suitable for quantitative measurements of motor incoordination in naive mice , 2004, Naunyn-Schmiedebergs Archiv für Pharmakologie und experimentelle Pathologie.

[58]  J. Harding.  Aging of the Eye , 2003 .